Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · MicroRNA in disease regulation · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Three decades of messenger RNA vaccine development10.1016/j.nantod.2019.100766 ↗
2. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients10.1001/jama.2021.4385 ↗
3. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation10.1038/s41551-019-0485-1 ↗
4. Self-assembled mRNA vaccines10.1016/j.addr.2020.12.014 ↗
5. mRNA nanomedicine: design and recent applications10.1002/EXP.20210217 ↗
6. Recent advances in mRNA vaccine technology10.1016/j.coi.2020.01.008 ↗
7. RNA therapies explained10.1038/d41586-019-03068-4 ↗
8. Bruce, brain disorders? Precisely10.1126/science.aab2358 ↗
9. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing10.1038/nrd.2018.109 ↗
10. Management of glioblastoma: State of the art and future directions
11. An integrative model of cellular states, plasticity, and genetics for glioblastoma10.1016/j.cell.2019.06.024 ↗
12. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment10.1016/j.jconrel.2018.05.008 ↗
13. Molecular targeted therapy of glioblastoma10.1016/j.ctrv.2019.101896 ↗
14. Translational nanomedicine boosts anti-PD1 therapy to eradicate orthotopic PTEN-negative glioblastoma10.1021/acsnano.0c03386 ↗
15. E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression10.1038/s41416-020-01032-y ↗
16. Reactivation of the tumour suppressor PTEN by mRNA nanoparticles enhances antitumour immunity in preclinical models10.1126/scitranslmed.aba9772 ↗
17. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer
18. PTEN signaling pathways in glioblastoma10.4161/cbt.7.9.6954 ↗
19. PTBP1 promotes the growth of breast cancer cells through the PTEN/Akt pathway and autophagy10.1002/jcp.26823 ↗
20. MiR-132 controls pancreatic beta cell proliferation and survival through Pten/Akt/Foxo3 signaling10.1016/j.molmet.2019.11.012 ↗
21. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles10.1002/adma.201902575 ↗
22. Deconvoluting lipid nanoparticle structure for messenger RNA delivery10.1021/acs.nanolett.0c01386 ↗
23. Intracranial delivery of synthetic mRNA to suppress glioblastoma10.1016/j.omto.2021.12.010 ↗
24. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA10.1038/s41551-018-0284-0 ↗
25. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing10.1038/s41563-020-00886-0 ↗
26. Synthetic mRNA nanoparticle-mediated restoration of p53 tumour suppressor sensitizes p53-deficient cancers to mTOR inhibition10.1126/scitranslmed.aaw1565 ↗
27. Crossing the blood-brain barrier with nanoparticles10.1016/j.jconrel.2017.12.015 ↗
28. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
29. Coagulation-inspired direct fibrinogen assay using plasmonic nanoparticles functionalized with red blood cell membranes10.1021/acsnano.0c08136 ↗
30. Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy10.1126/sciadv.aaw6870 ↗
31. Gradient redox-responsive and two-stage rocket-mimetic drug delivery system for improved tumour accumulation and safe chemotherapy10.1021/acs.nanolett.9b03340 ↗
32. Apolipoprotein E peptide-directed chimeric polymersomes mediate an ultrahigh-efficiency targeted protein therapy for glioblastoma10.1021/acsnano.8b05265 ↗
33. From adsorption to covalent bonding: Apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood–brain barrier10.1002/adtp.202000092 ↗
34. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy10.1021/acsnano.2c00320 ↗
35. Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy10.1021/acs.nanolett.9b04683 ↗
36. Brain-targeting metastatic tumor cell membrane cloaked biomimetic nanomedicines mediate potent chemodynamic and RNAi combinational therapy of glioblastoma10.1002/adfm.202209239 ↗
37. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles10.1039/C3NR06371B ↗
38. Endosomal size and membrane leakiness influence proton sponge-based rupture of endosomal vesicles10.1021/acsnano.7b07583 ↗
39. Carriers break barriers in drug delivery: Endocytosis and endosomal escape of gene delivery vectors10.1021/acs.accounts.9b00177 ↗
40. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery10.1038/nnano.2012.73 ↗
41. Chemical modulation of siRNA lipophilicity for efficient delivery10.1016/j.jconrel.2019.06.022 ↗
42. Phenylboronic acid-decorated chondroitin sulfate A-based theranostic nanoparticles for enhanced tumour targeting and penetration10.1002/adfm.201500680 ↗
43. Design of an amphiphilic iRGD peptide and self-assembling nanovesicles for improving tumour accumulation and penetration and the photodynamic efficacy of the photosensitizer10.1021/acsami.8b11699 ↗
44. Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy10.1126/sciadv.abm8011 ↗
45. Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood–brain barrier penetration and amyloid beta-targeting drug delivery10.1021/acs.molpharmaceut.6b00781 ↗
46. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier10.1073/pnas.1222742110 ↗
47. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases10.1016/j.jconrel.2019.04.031 ↗
48. Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo10.1016/j.jconrel.2021.07.048 ↗
49. The highways and byways of mRNA decay10.1038/nrm2104 ↗
50. Emerging mRNA technologies: delivery strategies and biomedical applications10.1039/D1CS00617G ↗
51. Retrovirus-based mRNA transfer for transient cell manipulation
52. Alphaviruses in gene therapy10.3390/v1010013 ↗
53. High performance mRNA transfection through carbonate apatite–cationic liposome conjugates10.1016/j.biomaterials.2009.02.050 ↗
54. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs10.1021/acs.nanolett.5b02497 ↗
55. Adeno-associated virus vector as a platform for gene therapy delivery10.1038/s41573-019-0012-9 ↗
56. The blood-brain barrier: Physiology and strategies for drug delivery
57. Pervasive genomic damage in experimental intracerebral hemorrhage: Therapeutic potential of a mechanistic-based carbon nanoparticle10.1021/acsnano.9b05821 ↗